Going Green in Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Going Green in Pharmaceuticals
The pharmaceutical majors forward projects in biocatalysis, solvent replacement, and other approaches in green chemistry.


Pharmaceutical Technology
Volume 33, Issue 2, pp. 44-46


Patricia Van Arnum
Going green by incorporating more environmentally friendly approaches to the synthesis of active pharmaceutical ingredients (APIs) and intermediates can help to increase manufacturing efficiency and costs. In keeping with the fundamentals of green chemistry (see sidebar, "The 12 principles of green chemistry)" pharmaceutical companies are using strategies such as solvent reduction and replacement, refining a chemical route, and biocatalysis to optimize certain API syntheses while achieving improved environmental profiles.

Eli Lilly's production of a neurokinin 1 antagonist

Eli Lilly and Company (Indianapolis, IN) developed a green-chemistry approach for the commercial production of an investigational new drug candidate, LY686017, an antagonist of the neurokinin 1 subtype of the tachykinin receptor. The drug, {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]-triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone, is in Phase II clinical trials. Lilly demonstrated the commercial route on a pilot-plant scale in 2006 at its facilities in Indianapolis. Two prior synthetic routes were executed at the pilot-plant scale at its Indianapolis and Mont Saint Guibert, Belgium, facilities (1).


(ILLUSTRATION BY M.MCEVOY, IMAGES: FRANK LUKASSECK, RYAN MCVAY, MEDIOIMAGES/PHOTODISC/GETTY IMAGES FIGURES ARE COURTESY OF US FOOD AND DRUG ADMINISTRATION.)
Eli Lilly used a metric similar to but not identical to Sheldon's Environmental (E)-factor, which evaluates the environmental impact of a chemical process by calculating the ratio of kilograms of waste to kilograms of product (2). Lilly's e-factor measures the total mass of all raw materials, including water, which are used to produce each kilogram of API. The new route for LY686017 has a net e-factor of 146 kg/kg of API, which is an 84% reduction compared with the original route of the drug. Key technology in the new route included a chemoselective nucleophilic aromatic substitution, which produced the drug in high entaniomeric excess (> 99%) despite the complexity of the structure and the potential for positional isomers from all five aromatic rings (1, 3).

J&J's route to darunavir


Figure 1: Chemical structure for darunavir.
Johnson & Johnson (New Brunswick, NJ) used green chemistry to improve the synthesis of darunavir, the API in its protease inhibitor, "Prezista" (see Figure 1). The new process reduced waste and raw materials by 46 tons, reduced hydrogen gas by 4800 m3 , and eliminated 96 tons of methylene chloride in 2006, the year when the drug was approved. The key gains of the route were: reduced solvent use; the separation of the acidification and quenching steps to eliminate the formation of hydrogen gas and the replacement of hydrochloric acid with methane sulfonic acid and addition of acetone to react with excess hydride to form isopropanol; and the replacement of a solvent system containing methylene chloride and triethylamine with a system containing acetonitrile and pyridine (1).

Merck's green process for raltegravir


Figure 2: Chemical structure for raltegravir.
Merck & Co. (Whitehouse Station, NJ) developed a green process for producing raltegravir, the API in "Isentress" (see Figure 2). Isentress was approved in 2007 to treat HIV. An important part of the process involves replacing the reagent methyl iodide with trimethylsulfoxonium iodide. With this change and other improvements, the E-factor for the process was reduced from 388 to 121. The new process also improved yield by 35% (1).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here